Compare NTLA & STGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTLA | STGW |
|---|---|---|
| Founded | 2014 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2016 | 2006 |
| Metric | NTLA | STGW |
|---|---|---|
| Price | $13.17 | $6.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 7 |
| Target Price | ★ $20.45 | $8.39 |
| AVG Volume (30 Days) | ★ 3.0M | 1.7M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $67,671,000.00 | ★ $2,909,000,000.00 |
| Revenue This Year | N/A | $13.27 |
| Revenue Next Year | $62.75 | $4.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.92 | 2.39 |
| 52 Week Low | $5.97 | $4.03 |
| 52 Week High | $28.24 | $7.17 |
| Indicator | NTLA | STGW |
|---|---|---|
| Relative Strength Index (RSI) | 51.34 | 61.48 |
| Support Level | $12.55 | $4.81 |
| Resistance Level | $14.32 | $6.50 |
| Average True Range (ATR) | 0.75 | 0.22 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 65.52 | 63.83 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Stagwell Inc is a challenger network using AI to deliver marketing and advertising solutions to its clients. It operates in five reportable segments: Marketing Services, Digital Transformation, Media and Commerce, Communications, and The Marketing Cloud. Maximum revenue is generated from the Marketing Services segment, which offers social media solutions, designs breakthrough brand campaigns, and creates immersive experiential marketing programs and social engagement strategies, helping clients connect with audiences across digital platforms. The various brands operating under this segment include 72 and Sunny, Anomaly, NRG, Harris Insights, TEAM, and Movers & Shaker. Geographically, the company generates maximum revenue from the United States, followed by the UK and other countries.